X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC LTD with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC LTD vs AUROBINDO PHARMA - Comparison Results

ALEMBIC LTD    Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC LTD AUROBINDO PHARMA ALEMBIC LTD/
AUROBINDO PHARMA
 
P/E (TTM) x 50.3 18.8 268.2% View Chart
P/BV x 2.1 3.8 55.5% View Chart
Dividend Yield % 0.5 0.3 146.8%  

Financials

 ALEMBIC LTD   AUROBINDO PHARMA
EQUITY SHARE DATA
    ALEMBIC LTD
Mar-18
AUROBINDO PHARMA
Mar-18
ALEMBIC LTD/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs72809 8.9%   
Low Rs34504 6.7%   
Sales per share (Unadj.) Rs4.7281.1 1.7%  
Earnings per share (Unadj.) Rs6.141.4 14.8%  
Cash flow per share (Unadj.) Rs6.250.9 12.3%  
Dividends per share (Unadj.) Rs0.202.50 8.0%  
Dividend yield (eoy) %0.40.4 99.2%  
Book value per share (Unadj.) Rs40.7199.4 20.4%  
Shares outstanding (eoy) m267.03585.88 45.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x11.32.3 482.3%   
Avg P/E ratio x8.715.9 54.6%  
P/CF ratio (eoy) x8.512.9 65.7%  
Price / Book Value ratio x1.33.3 39.5%  
Dividend payout %3.36.0 54.2%   
Avg Mkt Cap Rs m14,139384,630 3.7%   
No. of employees `000NA17.3 0.0%   
Total wages/salary Rs m20721,308 1.0%   
Avg. sales/employee Rs ThNM9,500.7-  
Avg. wages/employee Rs ThNM1,229.4-  
Avg. net profit/employee Rs ThNM1,397.9-  
INCOME DATA
Net Sales Rs m1,255164,666 0.8%  
Other income Rs m3701,020 36.3%   
Total revenues Rs m1,625165,686 1.0%   
Gross profit Rs m11137,718 0.3%  
Depreciation Rs m385,580 0.7%   
Interest Rs m2777 0.2%   
Profit before tax Rs m44232,380 1.4%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m248,183 0.3%   
Profit after tax Rs m1,63024,229 6.7%  
Gross profit margin %8.922.9 38.6%  
Effective tax rate %5.425.3 21.5%   
Net profit margin %129.814.7 882.5%  
BALANCE SHEET DATA
Current assets Rs m1,867121,878 1.5%   
Current liabilities Rs m59186,806 0.7%   
Net working cap to sales %101.621.3 477.2%  
Current ratio x3.21.4 224.9%  
Inventory Days Days94130 72.6%  
Debtors Days Days7468 107.6%  
Net fixed assets Rs m1,79181,037 2.2%   
Share capital Rs m534586 91.2%   
"Free" reserves Rs m10,324116,218 8.9%   
Net worth Rs m10,858116,804 9.3%   
Long term debt Rs m414,512 0.9%   
Total assets Rs m11,591211,052 5.5%  
Interest coverage x260.942.7 611.5%   
Debt to equity ratio x00 9.8%  
Sales to assets ratio x0.10.8 13.9%   
Return on assets %14.111.8 118.8%  
Return on equity %15.020.7 72.4%  
Return on capital %15.227.4 55.5%  
Exports to sales %1.50-   
Imports to sales %21.00-   
Exports (fob) Rs m19NA-   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1980,727 0.0%   
Fx outflow Rs m26434,700 0.8%   
Net fx Rs m-24446,027 -0.5%   
CASH FLOW
From Operations Rs m23619,548 1.2%  
From Investments Rs m-224-19,570 1.1%  
From Financial Activity Rs m-278,642 -0.3%  
Net Cashflow Rs m-158,922 -0.2%  

Share Holding

Indian Promoters % 64.0 54.1 118.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.0 2.5%  
FIIs % 9.7 27.7 35.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.1 10.2 255.9%  
Shareholders   54,701 69,601 78.6%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC LTD With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  GLENMARK PHARMA  ORCHID PHARMA LTD  

Compare ALEMBIC LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of the Sell-Off in Share Markets, September Quarter Results, and Top Cues in Focus Today(Pre-Open)

On Wednesday, share markets in India traded on a volatile note throughout the day and witnessed selling pressure during the closing hours and ended deep in red.

Related Views on News

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Oct 3, 2018 | Updated on Oct 3, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This Market Crash could be the Biggest Wealth Creating Opportunity Since 2008(Profit Hunter)

Oct 8, 2018

While widespread fear is the friend of a value investor, serving up bargain purchases; personal fear is an investor's biggest enemy.

My Top 3 Tips to Navigate the Market Crash(The 5 Minute Wrapup)

Oct 8, 2018

Steep corrections are never easy to handle. It's hard to watch the value of your shares drop so much. But you can take steps to make the most of it.

IPO Market Feels the Heat of the Market Crash(Sector Info)

Oct 12, 2018

The sentiments in primary market have also deteriorated amid the stock market correction. Most listed IPOs of 2018 are trading below their issue price.

Even If IL&FS Group Brought This Correction, this is Right Time to Buy & Sit Tight!(Chart Of The Day)

Oct 12, 2018

Even if IL&FS is the culprit, it may turn out to be a hero if you buy right and sit tight.

ICICI Prudential Manufacture In India Fund: A Make In India Prodigy, Should You Invest?(Outside View)

Oct 8, 2018

PersonalFN briefly explains if you should be investing in the NFO: ICICI Prudenetial Manufacture in India Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC LTD SHARE PRICE


Oct 17, 2018 (Close)

TRACK ALEMBIC LTD

  • Track your investment in ALEMBIC LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC LTD 8-QTR ANALYSIS

COMPARE ALEMBIC LTD WITH

MARKET STATS